Smart software aims to perfect antibiotic dosing in septic shock
NCT ID NCT04178148
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a computer program called BestDose could help doctors give the right amount of the antibiotic amikacin to patients with septic shock. The goal was to get drug levels in the ideal range after the second dose. 180 patients took part, and researchers checked if more patients reached target levels with the software's help.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- amikacin
- What this could lead to
- If successful, this approach could help doctors give the right dose of amikacin to septic shock patients more reliably, potentially improving survival.
- What could go wrong
- This is a completed early-stage study with 180 patients. The software may not work for all patients, and better drug levels don't guarantee better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
180 people
The number who actually took part.
- Started
-
Nov 2019
- Finished
-
Dec 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The patient or their legal representative must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient has septic shock according to the SEPSIS-3 definition in the 24 hours preceding inclusion, regardless of the source of infection * Patient having already received a first dose of amikacin in the 22 preceding hours * Patient with an expectation of receiving at least 2 doses of amikacin * Patient with available amikacin therapeutic drug monitoring Exclusion Criteria: * The subject is participating in an interventional study that could influence the primary outcome, or is in a period of exclusion determined by a previous study * The patient is pregnant, parturient or breastfeeding * Patient has a contra-indication or an allergy to treatment by amikacin * Patient is not expected to survive beyond 48 hours
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Shock, septic are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nimes
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ultrasound help doctors give the right amount of fluids in septic shock?
- New sensor could replace painful finger pricks for ICU patients
- Triple-Drug cocktail for septic shock shows promise in small trial
- Timing of steroids could save lives in sepsis
- New heart imaging study seeks clues in septic shock survival
- Fingertip test may rival blood test in sepsis care